ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.62
0.96%
US Tech 100
18,064.80
0.02%
S&P 500
5,277.51
0.80%
US Dollar vs CAD
1.36525
-0.01%
Bitcoin
67,707.83
0.34%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Canada
  5. TSX
  6. Eupraxia Pharmaceuticals Inc (EPRX)

  7. Eupraxia Pharmaceuticals Inc (EPRX) News

EPRX

Eupraxia Pharmaceuticals (EPRX)

Eupraxia Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:TSX:EPRX
DateTimeSourceHeadlineSymbolCompany
05/23/20244:00PMPR Newswire (US)Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisTSX:EPRXEupraxia Pharmaceuticals Inc
05/23/20244:00PMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisTSX:EPRXEupraxia Pharmaceuticals Inc
05/22/20246:00AMPR Newswire (US)Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024TSX:EPRXEupraxia Pharmaceuticals Inc
05/22/20246:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024TSX:EPRXEupraxia Pharmaceuticals Inc
05/21/20244:00PMPR Newswire (US)Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisTSX:EPRXEupraxia Pharmaceuticals Inc
05/21/20244:00PMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisTSX:EPRXEupraxia Pharmaceuticals Inc
05/14/20246:00AMPR Newswire (US)Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024TSX:EPRXEupraxia Pharmaceuticals Inc
05/14/20246:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024TSX:EPRXEupraxia Pharmaceuticals Inc
05/08/20244:03PMPR Newswire (US)Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateTSX:EPRXEupraxia Pharmaceuticals Inc
05/08/20244:03PMPR Newswire (Canada)Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateTSX:EPRXEupraxia Pharmaceuticals Inc
05/02/20246:00AMPR Newswire (US)Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory BoardTSX:EPRXEupraxia Pharmaceuticals Inc
05/02/20246:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory BoardTSX:EPRXEupraxia Pharmaceuticals Inc
04/11/20246:00AMPR Newswire (US)Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024TSX:EPRXEupraxia Pharmaceuticals Inc
04/11/20246:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024TSX:EPRXEupraxia Pharmaceuticals Inc
04/08/20246:00AMPR Newswire (US)Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor ConferenceTSX:EPRXEupraxia Pharmaceuticals Inc
04/08/20246:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor ConferenceTSX:EPRXEupraxia Pharmaceuticals Inc
04/05/20246:00AMPR Newswire (US)Eupraxia Pharmaceuticals Begins Trading on Nasdaq TodayTSX:EPRXEupraxia Pharmaceuticals Inc
04/05/20246:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Begins Trading on Nasdaq TodayTSX:EPRXEupraxia Pharmaceuticals Inc
04/03/20244:00PMPR Newswire (Canada)Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024TSX:EPRXEupraxia Pharmaceuticals Inc
04/03/20244:00PMPR Newswire (US)Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024TSX:EPRXEupraxia Pharmaceuticals Inc
04/01/20244:01PMPR Newswire (US)Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial ResultsTSX:EPRXEupraxia Pharmaceuticals Inc
04/01/20244:01PMPR Newswire (Canada)Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial ResultsTSX:EPRXEupraxia Pharmaceuticals Inc
03/12/20248:41AMPR Newswire (Canada)L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - EPRXTSX:EPRXEupraxia Pharmaceuticals Inc
03/12/20248:39AMPR Newswire (Canada)Canadian Investment Regulatory Organization Trade Resumption - EPRXTSX:EPRXEupraxia Pharmaceuticals Inc
03/11/20243:06PMPR Newswire (Canada)Suspension de la négociation par l'Organisme canadien de réglementation des investissements - EPRXTSX:EPRXEupraxia Pharmaceuticals Inc
03/11/20243:04PMPR Newswire (Canada)Canadian Investment Regulatory Organization Trading Halt - EPRXTSX:EPRXEupraxia Pharmaceuticals Inc
02/05/20244:00PMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces Updated Positive Clinical Data in EP-104GI RESOLVE Trial for the Treatment of Eosinophilic EsophagitisTSX:EPRXEupraxia Pharmaceuticals Inc
02/01/20246:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Initiates Phase 3 Development Program for EP-104IARTSX:EPRXEupraxia Pharmaceuticals Inc
01/30/20246:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces Positive Data from MRI Exploratory Sub-Study in Phase 2 SPRINGBOARD Trial Evaluating the Safety and Efficacy of EP-104IAR for the Treatment of Osteoarthritis of the KneeTSX:EPRXEupraxia Pharmaceuticals Inc
01/08/20245:44PMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces Filing of Preliminary MJDS Base Shelf ProspectusTSX:EPRXEupraxia Pharmaceuticals Inc
 Showing the most relevant articles for your search:TSX:EPRX

Your Recent History

USOTC
BMXI
Brookmount Explorations (PK)
USOTC
HMBL
HUMBL (PK)
USOTC
GNCP
GNCC Capital (CE)
USOTC
TPTW
TPT Global Tech (PK)
USOTC
CATV
4Cable TV (PK)
USOTC
DRNK
NoHo (PK)
AMEX
FOXO
FOXO Technologies
NASDAQ
COOP
Mr Cooper
USOTC
IFUS
Impact Fusion (PK)
USOTC
FSRN
Fisker (PK)
USOTC
VPLM
Voip Pal Com (QB)
USOTC
UBQU
Ubiquitech Software (PK)
USOTC
MWWC
Marketing Worldwide (PK)
USOTC
RNVA
Rennova Health (PK)
USOTC
KEGS
1812 Brewing (PK)
NASDAQ
DJT
Trump Media and Technology
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved